Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 5.6d

Immunosuppression Use for Maintenance by Regimen

Prior to Discharge, 2000 to 2009

Recipients with Kidney Transplants

  Transplant Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Functioning Graft at Discharge 13,116 13,823 14,324 14,691 15,543 16,012 16,670 16,260 16,129 16,485
With Immunosuppression Info 12,897 13,798 14,260 14,619 15,411 15,793 16,470 16,027 16,037 16,293
CyA 0.1% 0.1% 0.1% 0.2% 0.2% 0.1% 0.1% 0.1% 0.0% 0.0%
Tac 0.6% 1.1% 2.0% 1.0% 1.3% 1.4% 1.9% 1.5% 1.6% 1.9%
--- + MMF/MPA 0.1% 0.1% 0.2% 0.4% 0.4% 0.5% 0.5% 0.4% 0.9% 0.9%
CyA + MMF/MPA 0.9% 0.9% 0.7% 1.6% 1.7% 1.3% 2.0% 1.9% 0.8% 0.5%
Tac + MMF/MPA 1.1% 1.7% 2.9% 6.6% 13.7% 19.8% 24.4% 27.6% 28.4% 27.7%
--- + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0%
Tac + OtherAntimet 0.1% 0.1% 0.0% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1%
--- + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Siro/Evero 0.1% 0.3% 0.1% 0.2% 0.4% 0.2% 0.0% 0.1% 0.1% 0.1%
CyA + Siro/Evero 0.1% 0.1% 0.4% 0.9% 1.2% 1.2% 1.1% 0.9% 0.8% 0.7%
Tac + Siro/Evero 0.4% 1.2% 1.3% 1.7% 1.9% 1.1% 1.0% 0.6% 0.3% 0.1%
--- + MMF/MPA + Siro/Evero 0.1% 0.2% 0.2% 0.4% 0.6% 0.4% 0.5% 0.2% 0.2% 0.3%
CyA + MMF/MPA + Siro/Evero 0.1% 0.2% 0.2% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + Siro/Evero 0.1% 0.2% 0.3% 1.2% 0.7% 0.5% 0.4% 0.2% 0.2% 0.2%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Steroids 1.2% 1.0% 0.9% 1.3% 1.7% 1.3% 0.5% 0.3% 0.4% 0.7%
CyA + Steroids 3.1% 1.7% 1.2% 1.4% 1.4% 0.4% 0.3% 0.3% 0.1% 0.2%
Tac + Steroids 3.5% 3.9% 3.3% 2.3% 2.5% 2.3% 1.7% 2.0% 1.7% 2.8%
--- + MMF/MPA + Steroids 1.6% 1.4% 1.2% 1.6% 1.6% 2.0% 2.6% 2.0% 1.8% 1.4%
CyA + MMF/MPA + Steroids 37.0% 27.6% 22.9% 18.3% 14.2% 9.9% 6.7% 5.6% 4.5% 3.5%
Tac + MMF/MPA + Steroids 31.4% 38.5% 46.2% 46.8% 46.6% 50.3% 49.2% 51.9% 54.4% 56.0%
--- + OtherAntimet + Steroids 0.1% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Steroids 3.6% 2.2% 0.8% 0.4% 0.2% 0.1% 0.1% 0.1% 0.1% 0.0%
Tac + OtherAntimet + Steroids 1.1% 1.3% 1.1% 0.9% 0.5% 0.2% 0.3% 0.2% 0.3% 0.3%
--- + Siro/Evero + Steroids 0.5% 0.5% 0.4% 0.6% 0.4% 0.2% 0.1% 0.1% 0.1% 0.0%
CyA + Siro/Evero + Steroids 5.0% 3.6% 2.8% 2.2% 1.3% 1.2% 1.2% 0.9% 0.8% 0.4%
Tac + Siro/Evero + Steroids 4.4% 6.4% 4.8% 4.7% 3.5% 2.4% 2.9% 0.9% 0.4% 0.1%
Other Regimen 3.7% 5.5% 5.9% 4.9% 3.7% 3.1% 2.5% 2.0% 2.2% 2.0%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.